Curated News
By: NewsRamp Editorial Staff
June 24, 2026
Helus Pharma's Phase 3 Trial for Depression Drug Hits 86% Enrollment
TLDR
- Helus Pharma's Phase 3 trial for HLP003 is 86% enrolled, positioning it ahead in the race for novel depression treatments.
- HLP003, a serotonergic agonist with Breakthrough Therapy Designation, is being tested in Phase 3 APPROACH and PARADIGM trials for major depressive disorder.
- HLP003 aims to provide durable mental health improvements, addressing the unmet need for millions suffering from depression.
- Helus Pharma's HLP003, a synthetic molecule promoting neuroplasticity, targets serotonin pathways to potentially rewire the depressed brain.
Impact - Why it Matters
This milestone matters because major depressive disorder affects over 280 million people globally, and many patients do not respond adequately to existing treatments. Helus Pharma's HLP003, with its Breakthrough Therapy Designation, could offer a novel mechanism of action by promoting neuroplasticity through serotonin pathway activation. If successful, this drug could provide a new, effective option for treatment-resistant depression, potentially improving outcomes for millions. The progress of the APPROACH trial brings us closer to a new class of antidepressants that may offer durable relief, addressing a significant unmet medical need.
Summary
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has announced a significant milestone in its Phase 3 APPROACH clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder (MDD). Enrollment in the study has surpassed 86%, and the trial remains on track for completion. HLP003 is Helus Pharma's lead proprietary novel serotonergic agonist (NSA), designed to activate serotonin pathways believed to promote neuroplasticity. The drug has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address the large unmet need in mental health treatment. The APPROACH study is part of the broader PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. The company expects to report topline data from APPROACH in the fourth quarter of 2026, advancing HLP003 toward potential commercialization for patients suffering from MDD.
Helus Pharma is a clinical-stage pharmaceutical company founded in 2019, committed to developing proprietary NSAs that aim to provide durable improvements in mental health. In addition to HLP003, the company is developing HLP004, another proprietary NSA currently in Phase 2 for generalized anxiety disorder. The company's extensive research portfolio includes investigational NSAs targeting depression, anxiety, and other mental health conditions. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit the company's newsroom at https://ibn.fm/HELP or the company website at www.helus.com.
The announcement was disseminated by BioMedWire, a specialized communications platform focusing on the biotechnology, biomedical, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides a range of services including press release distribution, editorial syndication, and social media distribution. The full press release can be accessed at https://ibn.fm/Qpikw. This news highlights Helus Pharma's progress in addressing the critical need for effective treatments for major depressive disorder, a condition affecting millions worldwide.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma's Phase 3 Trial for Depression Drug Hits 86% Enrollment
